12/25/2023 0 Comments Stem cell biotech stock![]() ![]() is a clinical-stage company that is developing cell therapies designed to extend and enhance. ATHX (NASDAQ) Headquartered in Cleveland, Ohio, Atherys, Inc. ![]() All in all, the intention of acquisition is surely great news for TiGenix, which had been struggling financially for a few years before its first deal with Takeda. Whether your a stock investor, an industry executive, or a biotech aficionado, below are ten cell therapy companies that are developing intriguing technology platforms. “ We believe that TiGenix’s expertise would help accelerate Takeda’s ambition to develop novel stem cell therapies,” said Eduardo Bravo, CEO of TiGenix. The other, called AlloCSC-01, uses cardiac stem cells to help regenerate heart tissue after myocardial infarction. One is C圆11, also based on eASC technology, to treat sepsis in patients with pneumonia. ![]() With the acquisition of TiGenix, Takeda would also get hold of two other stem cell therapies in the company’s pipeline. It will support an application for US approval with the FDA, which has already granted orphan drug designation to the stem cell therapy. On top of the results of a Phase III that support the application for European approval of C圆01, TiGenix is currently running a second Phase III trial in the US. Vytrus Biotech is a biotechnology company that develops cosmetic active ingredients from plant stem cell technology at. The immunomodulatory effects of these cells have proven to help treat complex perianal fistulas, a highly debilitating complication of Crohn’s disease that remains difficult to treat. The EMA’s Committee for Medicinal Products for Human Use (CHMP) backed the approval of the therapy in December, and a final decision is expected in the first half of 2018.Ĭ圆01 is a cell therapy consisting of stem cells derived from the fat tissue of a donor, known as expanded adipose-derived stem cells (eASCs). If it goes through, the deal will amount to about €520M.īut first, Takeda has to wait for approval by the Belgian Financial Services and Markets Authority, and TiGenix has to meet the condition of obtaining EMA approval for its lead stem cell therapy, called C圆01. Short of two years after partnering with TiGenix for the development of a stem cell therapy, Takeda has offered to buy the remaining shares of the company in Euronext Brussels and the Nasdaq and turn it into a wholly-owned subsidiary. Takeda has offered to acquire TiGenix subject to the upcoming European approval of its lead stem cell therapy for Crohn’s disease, C圆01. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |